Cue Biopharma is trading 6% down at $26.77 as the stock undergoes consolidation following a sharp multi-day rally driven by positive partnership and financing news.
- The stock recently surged following the announcement of a $50 million private placement and a $7.5 million milestone payment.
- Today's price action appears to be driven by profit-taking rather than any new company-specific developments or negative catalysts.